Advertisement

Topics

Acute Migraine Treatment Meets Primary and Key Secondary Endpoints

06:05 EDT 7 Aug 2017 | PharmPro

Lilly announces positive results for second Phase 3 study of lasmiditan for the acute treatment of migraine. The company plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2018.
Contributed Author: 
Eli Lilly and Company

Original Article: Acute Migraine Treatment Meets Primary and Key Secondary Endpoints

NEXT ARTICLE

More From BioPortfolio on "Acute Migraine Treatment Meets Primary and Key Secondary Endpoints"

Quick Search
Advertisement
 

Relevant Topics

Lilly
Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in over 50 countries with just under 40,000 employees. Appr...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...